Papaverine

DB01113

small molecule approved investigational

Deskripsi

An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.

Struktur Molekul 2D

Berat 339.385
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 0.5-2 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

625 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Papaverine.
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Papaverine is combined with Duloxetine.
Risperidone Papaverine may increase the hypotensive activities of Risperidone.
Levodopa The therapeutic efficacy of Levodopa can be decreased when used in combination with Papaverine.
Nicorandil Nicorandil may increase the hypotensive activities of Papaverine.
Linezolid Linezolid may increase the orthostatic hypotensive activities of Papaverine.
Furazolidone Furazolidone may increase the orthostatic hypotensive activities of Papaverine.
Procaine Procaine may increase the orthostatic hypotensive activities of Papaverine.
Tranylcypromine Tranylcypromine may increase the orthostatic hypotensive activities of Papaverine.
Phenelzine Phenelzine may increase the orthostatic hypotensive activities of Papaverine.
Minaprine Minaprine may increase the orthostatic hypotensive activities of Papaverine.
Selegiline Selegiline may increase the orthostatic hypotensive activities of Papaverine.
Procarbazine Procarbazine may increase the orthostatic hypotensive activities of Papaverine.
Moclobemide Moclobemide may increase the orthostatic hypotensive activities of Papaverine.
Isocarboxazid Isocarboxazid may increase the orthostatic hypotensive activities of Papaverine.
Rasagiline Rasagiline may increase the orthostatic hypotensive activities of Papaverine.
Pargyline Pargyline may increase the orthostatic hypotensive activities of Papaverine.
Clorgiline Clorgiline may increase the orthostatic hypotensive activities of Papaverine.
Iproniazid Iproniazid may increase the orthostatic hypotensive activities of Papaverine.
Nialamide Nialamide may increase the orthostatic hypotensive activities of Papaverine.
Safinamide Safinamide may increase the orthostatic hypotensive activities of Papaverine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Papaverine.
Methylene blue Methylene blue may increase the orthostatic hypotensive activities of Papaverine.
Hydracarbazine Hydracarbazine may increase the orthostatic hypotensive activities of Papaverine.
Pirlindole Pirlindole may increase the orthostatic hypotensive activities of Papaverine.
Toloxatone Toloxatone may increase the orthostatic hypotensive activities of Papaverine.
Benmoxin Benmoxin may increase the orthostatic hypotensive activities of Papaverine.
Mebanazine Mebanazine may increase the orthostatic hypotensive activities of Papaverine.
Octamoxin Octamoxin may increase the orthostatic hypotensive activities of Papaverine.
Pheniprazine Pheniprazine may increase the orthostatic hypotensive activities of Papaverine.
Phenoxypropazine Phenoxypropazine may increase the orthostatic hypotensive activities of Papaverine.
Pivhydrazine Pivhydrazine may increase the orthostatic hypotensive activities of Papaverine.
Safrazine Safrazine may increase the orthostatic hypotensive activities of Papaverine.
Caroxazone Caroxazone may increase the orthostatic hypotensive activities of Papaverine.
Harmaline Harmaline may increase the orthostatic hypotensive activities of Papaverine.
Brofaromine Brofaromine may increase the orthostatic hypotensive activities of Papaverine.
Butalbital Butalbital may increase the hypotensive activities of Papaverine.
Pentobarbital Pentobarbital may increase the hypotensive activities of Papaverine.
Secobarbital Secobarbital may increase the hypotensive activities of Papaverine.
Methohexital Methohexital may increase the hypotensive activities of Papaverine.
Thiopental Thiopental may increase the hypotensive activities of Papaverine.
Primidone Primidone may increase the hypotensive activities of Papaverine.
Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Papaverine.
Thiamylal Thiamylal may increase the hypotensive activities of Papaverine.
Phenobarbital Phenobarbital may increase the hypotensive activities of Papaverine.
Amobarbital Amobarbital may increase the hypotensive activities of Papaverine.
Hexobarbital Hexobarbital may increase the hypotensive activities of Papaverine.
Barbital Barbital may increase the hypotensive activities of Papaverine.
Barbexaclone Barbexaclone may increase the hypotensive activities of Papaverine.
Butabarbital Butabarbital may increase the hypotensive activities of Papaverine.
Dofetilide The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dofetilide.
Citalopram The risk or severity of QTc prolongation can be increased when Papaverine is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Papaverine is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Papaverine is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Papaverine is combined with Valproic acid.
Terfenadine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Terfenadine.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Papaverine is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quinine.
Sotalol The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sotalol.
Erlotinib The risk or severity of QTc prolongation can be increased when Papaverine is combined with Erlotinib.
Toremifene The risk or severity of QTc prolongation can be increased when Papaverine is combined with Toremifene.
Cisapride The risk or severity of QTc prolongation can be increased when Papaverine is combined with Cisapride.
Imatinib The risk or severity of QTc prolongation can be increased when Papaverine is combined with Imatinib.
Astemizole The risk or severity of QTc prolongation can be increased when Papaverine is combined with Astemizole.
Thioridazine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Thioridazine.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Papaverine is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mifepristone.
Cocaine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Cocaine.
Quinidine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quinidine.
Procainamide The risk or severity of QTc prolongation can be increased when Papaverine is combined with Procainamide.
Pimozide The risk or severity of QTc prolongation can be increased when Papaverine is combined with Pimozide.
Amiodarone The risk or severity of QTc prolongation can be increased when Papaverine is combined with Amiodarone.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Papaverine is combined with Arsenic trioxide.
Escitalopram The risk or severity of QTc prolongation can be increased when Papaverine is combined with Escitalopram.
Domperidone The risk or severity of QTc prolongation can be increased when Papaverine is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Halofantrine.
Bepridil The risk or severity of QTc prolongation can be increased when Papaverine is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Papaverine is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Papaverine is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Papaverine is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Tetrabenazine.
Dronedarone The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dronedarone.
Nilotinib The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nilotinib.
Iloperidone The risk or severity of QTc prolongation can be increased when Papaverine is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when Papaverine is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when Papaverine is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Papaverine is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lumefantrine.
Vemurafenib The risk or severity of QTc prolongation can be increased when Papaverine is combined with Vemurafenib.
Eliglustat The risk or severity of QTc prolongation can be increased when Papaverine is combined with Eliglustat.
Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Papaverine.
Glasdegib The risk or severity of QTc prolongation can be increased when Papaverine is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Papaverine is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Papaverine is combined with Terodiline.

Target Protein

3',5'-cyclic-AMP phosphodiesterase 4D PDE4D
cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A
3',5'-cyclic-AMP phosphodiesterase 4B PDE4B
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A PDE10A
Phosphodiesterase enzymes PDE4D

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15457029
    Tang Y, Luan J, Zhang X: Accelerating tissue expansion by application of topical papaverine cream. Plast Reconstr Surg. 2004 Oct;114(5):1166-9.
  • PMID: 16159054
    Liu JK, Couldwell WT: Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2005;2(2):124-32.
  • PMID: 15519189
    Takeuchi K, Sakamoto S, Nagayoshi Y, Nishizawa H, Matsubara J: Reactivity of the human internal thoracic artery to vasodilators in coronary artery bypass grafting. Eur J Cardiothorac Surg. 2004 Nov;26(5):956-9.

Contoh Produk & Brand

Produk: 12 • International brands: 39
Produk
  • Papaverine Hydrochloride
    Injection, solution • 30 mg/1mL • Intramuscular; Intravenous • US
  • Papaverine Hydrochloride
    Injection, solution • 30 mg/1mL • Intramuscular; Intravenous • US
  • Papaverine Hydrochloride
    Injection, solution • 30 mg/1mL • Intramuscular; Intravenous • US
  • Papaverine Hydrochloride
    Injection, solution • 30 mg/1mL • Intramuscular; Intravenous • US
  • Papaverine Hydrochloride
    Injection, solution • 30 mg/1mL • Intramuscular; Intravenous • US
  • Papaverine Hydrochloride
    Injection, solution • 30 mg/1mL • Intramuscular; Intravenous • US
  • Papaverine Hydrochloride
    Injection, solution • 30 mg/1mL • Intravenous • US
  • Papaverine Hydrochloride
    Injection, solution • 30 mg/1mL • Intravenous • US
Menampilkan 8 dari 12 produk.
International Brands
  • Alapav
  • Albatran
  • Artegodan
  • Cardioverina
  • Cerebid
  • Cerespan
  • Delapav
  • Dilaves
  • Dispamil
  • Drapavel

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul